708 results on '"Bacher, U."'
Search Results
52. Evaluation of BM cytomorphology after allo-SCT in patients with MDS
53. Circulating CD34+ cells as prognostic and follow-up marker in patients with myelofibrosis undergoing allo-SCT
54. Similar patterns of chromosome abnormalities in CML occur in addition to the Philadelphia chromosome with or without tyrosine kinase inhibitor treatment
55. Penetration und Metabolisierung von Glucocorticoiden bei Hautäquivalenten und exzidierter Humanhaut
56. Circulating CD34+ cells as prognostic and follow-up marker in patients with myelofibrosis undergoing allogeneic stem cell transplantation: P1160
57. Evaluation of allogeneic haematopoietic stem cell transplantation and pre- and post-transplant therapy in high-risk patients with chronic myeloid leukaemia: P1151
58. CD34+-selected stem cell boost for poor graft function after allogeneic haematopoietic stem cell transplantation: P1089
59. In haematopoietic SCT recipients, pre- and posttransplant cytomorphologic remission status has strong prognostic relevance, but no predictive value during reduced-conditioning phase in AML patients: P936
60. Disease-specific recovery of regulatory T-cell after allogeneic stem cell transplantation: P729
61. Validation of several prognositic models for prediction of survival after reduced-intensity transplantation for myelofibrosis: O411
62. Outcome of allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia with 11q23 (MLL) rearrangement (MLL-r AML). A retrospective analysis from the Acute Leukaemia Working Party of EBMT: O275
63. Outcome of allo-SCT for chronic myelomonocytic leukemia
64. Relapse-therapy for myelofibrosis patients after allogeneic stem cell transplantation: V761
65. Selected Abstract Utility of JAK2V617F and MPLW515L/K mutation analysis in the setting of allogeniec stem cell transplantation for myelofibrosis: V109
66. Multilineage Dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: A comparison of 408 cases classified as “AML not otherwise specified” (AML-NOS) or “AML with myelodysplasia-related changes” (AML-MRC): V30
67. MUTYH-associated polyposis – variability of the clinical phenotype in patients with biallelic and monoallelic MUTYH mutations and report on novel mutations
68. A new case with rare e6a2 BCR–ABL fusion transcript developing two new resistance mutations during imatinib mesylate, which were replaced by T315I after subsequent dasatinib treatment
69. Detection of an MPLW515 mutation in a case with features of both essential thrombocythemia and refractory anemia with ringed sideroblasts and thrombocytosis
70. Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma: V298
71. Dose-reduced conditioning followed by allogeneic stem cell transplantation in patients with myelofibrosis: results from a multicenter prospective trial of the chronic leukemia working party of the european group for blood and marrow transplantation (EBMT): 222
72. Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma: O157
73. HLA-mismatched unrelated donors as alternative graft source for allogeneic stem cell transplantation after ATG-containing conditioning regimen: O147
74. JAK2V617F as progression marker in CMPD and as cooperative mutation in AML with trisomy 8 and t(8;21): a comparative study on 1103 CMPD and 269 AML cases
75. Report on two novel nucleotide exchanges in the JAK2 pseudokinase domain: D620E and E627E
76. Prospective multicentre study of dose-reduced conditioning followed by allogeneic stem cell transplantation in patients with myelofibrosis. A study of the MDS subcommittee of the Chronic Leukaemia Working Party of the EBMT
77. TP53 Status As Well As Cytogenetic Complexity Significantly Impact on Prognosis in Myelodysplastic Syndromes with Complex (>= 3 anomalies) Aberrant Karyotypes
78. A new, simple prognostic system for complex aberrant myelodysplastic syndromes and secondary AML
79. JAK2 seems to be a typical cooperating mutation in therapy-related t(8;21)/AML1-ETO-positive AML
80. Erythroblastic synartesis in a patient initially diagnosed with myelodysplastic syndrome
81. Genetic instability and TP53 alterations in MDS and sAML with complex aberrant karyotype
82. JAK2 seems to be a typical cooperating mutation in therapy-related t(8;21)/ AML1-ETO-positive AML
83. Iron-overload links to genetic instability in myelodysplastic syndromes
84. Nachweis einer signifikanten Korrelation von Eisenüberladung mit erhöhter genetischer Instabilität mittels umfassender genetischer Analysen bei Patienten mit Myelodysplastischen Syndromen
85. Erratum: Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma
86. Significance of Molecular and Cytogenetic TP53 Status in MDS with Complex Karyotypes
87. Increased Serum Ferritin and Genetic Instability in Myelodysplastic Syndromes
88. Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5)
89. Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma
90. Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor
91. 175 - Significance of Molecular and Cytogenetic TP53 Status in MDS with Complex Karyotypes
92. 54 - Increased Serum Ferritin and Genetic Instability in Myelodysplastic Syndromes
93. WT1 mutations are secondary events in AML, show varying frequencies and impact on prognosis between genetic subgroups
94. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes
95. Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease
96. Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how?
97. P-053 Characterization of 305 patients with myelodysplastic syndromes and 20q-deletion: Cytomorphological features, and concomitant cytogenetic and molecular genetic alterations
98. The benefit of population-based studies for older patients with acute myeloid leukemia
99. Diagnostik akuter Leukämien
100. Evaluation of BM cytomorphology after allo-SCT in patients with MDS
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.